Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDYL2 | Q8N8U2 | 6/20 | 0.87 |
| ▸ | CBX7 | O95931 | 4/20 | 0.87 |
| ▸ | CBX8 | Q9HC52 | 4/20 | 0.87 |
| ▸ | CBX4 | O00257 | 3/20 | 0.87 |
| ▸ | CBX6 | O95503 | 1/20 | 0.73 |
| ▸ | CBX2 | Q14781 | 1/20 | 0.73 |
| ▸ | REN | P00797 | 3/20 | 0.43 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23718040 | 1.00 | CDYL2 (0.87) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL23682719 | 1.00 | CDYL2 (0.87) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL26219950 | 1.00 | CDYL2 (0.87) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL23717921 | 1.00 | CDYL2 (0.87) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL23815561 | 0.93 | CDYL2 (0.78) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL24510752 | 0.93 | CDYL2 (0.78) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL23718039 | 0.93 | CDYL2 (0.75) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL23815796 | 0.93 | CDYL2 (0.75) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL24510878 | 0.92 | CDYL2 (0.74) | CDYL2CBX7CBX8CBX4CBX6 | |
| SCHEMBL23682653 | 0.91 | CDYL2 (0.72) | CDYL2CBX7CBX8CBX4CBX6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | claimed |
| EP-4154876-B1 | CBX7 INHIBITOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF A BLOOD VESSEL DISORDER | UNIV POTSDAM (DE) | 2024-07-10 | — | — | EP | claimed |
| EP-4154876-A1 | CBX7 INHIBITOR FOR USE IN THE TREATMENT AND/OR PREVENTION OF A BLOOD VESSEL DISORDER | Universität Potsdam (DE) | 2023-03-29 | — | — | EP | claimed |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-10-02 | — | — | US | disclosed |
| US-12419900-B2 | Induction of synthetic lethality with epigenetic therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250276997-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-20250177566-A1 | USE OF CHEMICAL EPIGENETIC MODIFIERS TO MODULATE GENE EXPRESSION | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-06-05 | — | — | US | disclosed |
| US-20250163028-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2025-05-22 | — | — | US | disclosed |
| US-20250144226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2025-05-08 | — | — | US | disclosed |
| US-20250144221-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2025-05-08 | — | — | US | disclosed |
| EP-4540249-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | Yeda Research and Development Co. Ltd (IL) | 2025-04-23 | — | — | EP | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| CN-111214659-B | Application of CBX4 inhibitor in preparation of esophageal squamous carcinoma radiosensitizer | 复旦大学附属肿瘤医院 | 2023-02-10 | — | — | CN | disclosed |
| EP-4100525-A1 | METHODS OF TREATMENT OF CANCER DISEASE BY TARGETING AN EPIGENETIC FACTOR | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-12-14 | — | — | EP | disclosed |
| US-11491174-B2 | Induction of synthetic lethality with epigenetic therapy | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-11-08 | — | — | US | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11491174-B2 | Induction of synthetic lethality with epigenetic therapy | MCL1, BAD, ACIN1 | CDYL2 314/4885CBX7 99/4885CBX8 130/4885 |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | CDYL2 1804/4885CBX7 1030/4885CBX8 1268/4885 |
| US-12419900-B2 | Induction of synthetic lethality with epigenetic therapy | MCL1, BAD, ACIN1 | CDYL2 314/4885CBX7 99/4885CBX8 130/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CDYL2 621/4885CBX7 1336/4885CBX8 541/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | CDYL2 251/4885CBX7 300/4885CBX8 169/4885 |
| US-20250276997-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2, ATXN2L, ATXN10 | CDYL2 1642/4885CBX7 1216/4885CBX8 1474/4885 |
| US-20250144226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CLN6, CACYBP, CREBBP | CDYL2 112/4885CBX7 406/4885CBX8 302/4885 |
| US-20250177566-A1 | USE OF CHEMICAL EPIGENETIC MODIFIERS TO MODULATE GENE EXPRESSION | CTCF, FKBP1A, CHP1 | CDYL2 2439/4885CBX7 114/4885CBX8 279/4885 |
| US-20250144221-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | CDYL2 251/4885CBX7 300/4885CBX8 169/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | CDYL2 139/4885CBX7 1122/4885CBX8 492/4885 |
| US-20250304585-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (COLDR) COMPOUNDS | CASR, NPSR1, GSR | CDYL2 3002/4885CBX7 2869/4885CBX8 3593/4885 |
| US-20250163028-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | UBQLN2, NEDD4, UBTF | CDYL2 1134/4885CBX7 1488/4885CBX8 1090/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | CDYL2 1159/4885CBX7 1599/4885CBX8 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.